Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]

2025年12月7日，国家医疗保障局公布2025年国家医保药品目录调整结果，轩竹生物自主研发的1类创新 药、CDK4/6抑制剂吡洛西利片成功纳入目录，为晚期乳腺癌患者带来医保报销新福利。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中轩竹生物- B(02575)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，轩竹生物有可能被调入港股 通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Baoyi Pharmaceutical-B (02659) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Summary - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which has "best-in-class" potential in terms of low pre-stored antibodies and administration frequency for antibody-mediated autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration for assisted reproduction [1] - These three core products are in various stages of commercialization, new drug application registration, or later clinical stages in China, indicating a transition from pure research and development to commercialization for Baoyi Pharmaceutical [1] Industry Summary - The adjustment of Hong Kong Stock Connect eligible stocks is often seen as a market barometer [1] - If Baoyi Pharmaceutical successfully enters the Stock Connect, it is expected to significantly enhance stock liquidity and valuation premium, providing mainland investors with new opportunities to allocate quality biopharmaceutical assets [1]

智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中不同集团(06090)获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年 3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。机构指出，不同集团有望 借此机会纳入港股通，迎来发展新契机。 港股通标的的调整历来备受市场关注，不仅直接影响相关个股的市场流动性、估值定价，更能为内地投 资者挖掘新的优质投资标的，实现资金与优质资产的精准对接。 此前，根据LiveReport大数据测算，本次恒生综指纳入的市值门槛约为93亿港元。中金研报指出，不同 集团有可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 资料显示，不同集团前瞻性地聚焦于高端母婴品牌细分市场。自2019年推出高端母婴品牌BeBeBus以 来，不同集团以差异化战略快速崛起，凭借先发优势迅速占领用户心智，已成为这一细分赛道的佼佼 者。据弗若斯特沙利文数据，按2024年的GMV计算，BeBeBus在中国面向中高端消费者的耐用型育儿 产品品牌中排名第一，市场优势地位稳固。 值得注 ...

智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中劲方医药-B(02595)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3 月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，劲方医药有 可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 交银国际近期发布研报称，首次覆盖劲方医药，给予买入评级，目标价51港元。交银国际表示，作为一 家扎根中国内地、拥有全球视野的创新药企，劲方医药组建了一支平均拥有逾20年行业经验、执行力较 强的核心管理团队，建立了一条包括6款临床阶段候选药物的药物管线。 ...

Group 1 - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series as of December 31, 2025, with Pagoda Biopharma-B (02565) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report from CICC, Pagoda Biopharma is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Pagoda Biopharma recently announced that all conditions of the placement agreement have been fulfilled, with the placement completed on December 22, 2025 [1] - Under the terms of the placement agreement, the joint placement agents sold a total of 5.136 million shares at a price of HKD 58.41 per share to no fewer than six subscribers, representing approximately 1.81% of the enlarged H-shares and about 1.31% of the total shares after the placement [1]

Group 1 - The core point of the article is that Hedi Intelligent Driving (03881) has been included in the Hang Seng Composite Index, with changes effective from March 9, 2026, following the quarterly review by the Hang Seng Index Company [1] - The inclusion in the index may lead to Hedi Intelligent Driving being added to the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - According to Everbright Securities, Hedi Intelligent Driving is expected to reduce its Non-IFRS net loss to 76 million yuan in 2025, a year-on-year decrease of 39.8%, and forecasted to achieve Non-IFRS net profits of 75 million yuan and 357 million yuan in 2026 and 2027 respectively [1] Group 2 - The company is anticipated to accelerate the deployment of its autonomous mining vehicles, leveraging its technological, scenario, and commercialization advantages to maintain a leading position in the industry [1] - Everbright Securities has initiated coverage on Hedi Intelligent Driving with a "Buy" rating, reflecting confidence in the company's growth prospects [1]

Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Updates - Valiant Bio-B is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company announced that the first patient has successfully received treatment in the Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] Group 2: Clinical Research - The trial aims to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple-negative breast cancer [1]

威胜控股公布，公司已根据上市规则第15项应用指引就建议分拆向香港联交所提交建议，而香港联交所 已确认公司可继续进行建议分拆。 于2026年1月27日，惟远能源透过其独家保荐人向香港联交所递交上 市申请表格( A1表格)，申请惟远能源股份在香港联交所主板上市及买卖。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中威胜控股(03393)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9 日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，威胜控股有可能 被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

耀才证券金融截至2025年9月30日止六个月的中期业绩显示，收入4.97亿港元，同比增长10.72%；净利 润3.27亿港元，同比增长4.77%；基本每股盈利19.26港仙。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中耀才证券金融(01428)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年 3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，耀才证券金 融有可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...